Xiamen Humanity Hospital
Basalioma treatment cost in China is significantly more affordable than in the US, with primary procedures like Mohs microsurgery ranging from $2,400 to $4,500. Total expenses depend on tumor complexity, hospital tier, and chosen technique, such as cryodestruction, which runs from $6,200 to $13,500. International patients typically save 50-80% compared to Western rates. Top medical hubs for oncology include Guangzhou, Xiamen, and Shanghai.
Typical Basalioma Treatment Costs in China
Bookimed Expert Insight: For advanced cases, specialized oncology centers in Guangzhou offer higher value than general clinics. Fuda Cancer Hospital provides cryosurgery and over 10 types of minimally invasive therapies for late-stage patients. Those seeking academic expertise should consider Xiamen Humanity Hospital, where Professor Liu Shi Xin leads multidisciplinary care. These JCI-accredited facilities offer modern infrastructure at significantly lower costs than private Western hospitals.
| China | Turkey | Austria | |
| Mohs microsurgery | from $2,400 | from $2,200 | from $4,000 |
| Cryodestruction | from $6,200 | from $3,500 | from $4,000 |
| Wide excision of melanoma | from $4,500 | from $1,800 | - |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Mohs micrographic surgery is not widely available in all Chinese hospitals. It is highly concentrated in JCI-accredited facilities and top-tier oncology hubs in Beijing, Shanghai, and Guangzhou. Specialized centers like Fuda Cancer Hospital offer micrographic tumor tracking for complex facial basal cell carcinoma cases.
Bookimed Expert Insight: While patients often search specifically for Mohs surgery by name, Bookimed data shows that Xiamen Humanity Hospital and other large tertiary centers treat over 1,000,000 patients annually using oncologic plastic surgery. When exact Mohs terminology is not used, asking for frozen-section margin control often identifies the same high-precision, tissue-sparing results for facial lesions.
Patient Consensus: Patients emphasize going to the largest possible university or cancer center for facial tumors. They notes it is vital to confirm both tumor removal and reconstructive plastic surgery are available at the same hospital.
Reconstructive options in China after Basalioma excision include local skin flaps, full-thickness grafts, and microsurgical free flaps. Chinese oncology centers utilize a reconstructive ladder approach. Surgeons prioritize matching skin texture and preserving vital functions like eyelid closure. JCI-accredited facilities often perform these procedures.
Bookimed Expert Insight: Data from major Chinese tertiary centers like Xiamen Humanity Hospital shows a massive scale of operations, with around 1,000,000 patients treated annually. This high volume allows surgical teams to specialize in niche reconstructions. For example, Dr. Liu Shi Xin at Xiamen focuses on precise tumor management. Patients often find that specialized oncology hospitals provide more integrated care than general plastic surgery clinics. This ensures clear margins before the final reconstruction begins.
Patient Consensus: Patients emphasize that preserving functions like blinking or nasal airflow is more important than a perfect scar. Many note that flap surgery usually looks more natural than skin grafts for facial repairs.
Patients can receive non-surgical treatments like photodynamic therapy and cryotherapy for basalioma in China. These therapies are available at JCI-accredited cancer centers and large tertiary hospitals. Specialists often reserve these options for superficial lesions or patients unable to undergo traditional surgery.
Bookimed Expert Insight: While many general hospitals offer cryotherapy, international patients benefit from choosing oncology-specific centers like Fuda Cancer Hospital. This facility focuses on minimally invasive therapies instead of standard chemotherapy for advanced cases. Their JCI accreditation confirms they meet global safety standards for complex procedures like cryosurgery and NanoKnife.
Patient Consensus: Patients note that while non-surgical options are available, doctors often recommend surgery first for better precision. It is important to confirm the pathology subtype as these treatments work best for superficial lesions.
Odomzo (sonidegib) is the primary targeted systemic therapy approved in China for advanced basal cell carcinoma. The National Medical Products Administration (NMPA) cleared this oral Hedgehog inhibitor specifically for adult patients with locally advanced disease who cannot undergo surgery or radiation.
Bookimed Expert Insight: Xiamen Humanity Hospital is a tertiary facility accredited for Phase I–IV drug trials. This is crucial for advanced cases. If standard therapies like sonidegib fail, these accredited centers provide legal pathways to clinical trials for next-generation Hedgehog inhibitors.
Patient Consensus: Patients note that drug approval does not always guarantee immediate hospital availability. They recommend checking the specific pharmacy formulary at large cancer centers before traveling for treatment.
International patients choose China for Basalioma care to access advanced non-invasive therapies and high-volume oncology centers. Specialized facilities utilize cryodestruction and targeted molecular therapies. These centers provide rapid scheduling for complex cases. Many institutions hold JCI accreditation for safety.
Bookimed Expert Insight: China's oncology landscape is defined by massive scale and specialized research hubs. Xiamen Humanity Hospital serves 1,000,000 patients annually and manages Phase I-IV drug trials. This high volume allows surgeons like Dr. Liu Shi Xin to gain deep expertise in precision radiotherapy for complex malignancies. Patients benefit from this concentrated clinical experience which is rarely matched in smaller regional healthcare systems.
Patient Consensus: Patients value the rapid transition from initial assessment to surgery in modern tertiary hospitals. They emphasize the importance of confirming the pathology reporting process and arranging English-speaking support before arrival.